Selected studies investigating conditioning regimens and intensities in MF
| Study . | Regimen . | Survival . | Nonrelapse mortality . | Relapse . | |
|---|---|---|---|---|---|
| McLornan et al82 (RIC vs MAC) | Busulfan/fludarabine (57%) | Busulfan/fludarabine (47%) | 5 y: 53% vs 51% | 3 y: 32% vs 33% | 3 y: 17% vs 20% |
| Patriarca et al90 (RIC) | Busulfan/fludarabine | Thiotepa/fludarabine | 2 y: 54% vs 70% | 2 y: 21% vs 21% | 2 y: 36% vs 24% |
| Kröger et al58 (RIC) | Busulfan/fludarabine | 5 y: 56% | 1 y: 21% | 5 y: 25% | |
| Gupta et al80 (RIC) | Busulfan/fludarabine (38%), fludarabine/melphalane (28%), fludarabine/TBI (22%) | 5 y: 47% | 3 y: 22% | 3 y: 47% | |
| Gagelmann et al29 (RIC vs MAC) | Busulfan/fludarabine (63%) | Busulfan/cyclophosphamide (59%) | 6 y: 63% vs 59% | 2 y: 26% vs 29% | 2 y: 10% vs 9% |
| Murthy et al75 | Fludarabine/melphalane (66%), busulfan/fludarabine (34%) | Busulfan/fludarabine (65%), busulfan/cyclophosphamide (35%) | 2 y: 57% vs 72%∗ | 1 y: 20% vs 16% | 1 y: 49% vs 41% |
| Study . | Regimen . | Survival . | Nonrelapse mortality . | Relapse . | |
|---|---|---|---|---|---|
| McLornan et al82 (RIC vs MAC) | Busulfan/fludarabine (57%) | Busulfan/fludarabine (47%) | 5 y: 53% vs 51% | 3 y: 32% vs 33% | 3 y: 17% vs 20% |
| Patriarca et al90 (RIC) | Busulfan/fludarabine | Thiotepa/fludarabine | 2 y: 54% vs 70% | 2 y: 21% vs 21% | 2 y: 36% vs 24% |
| Kröger et al58 (RIC) | Busulfan/fludarabine | 5 y: 56% | 1 y: 21% | 5 y: 25% | |
| Gupta et al80 (RIC) | Busulfan/fludarabine (38%), fludarabine/melphalane (28%), fludarabine/TBI (22%) | 5 y: 47% | 3 y: 22% | 3 y: 47% | |
| Gagelmann et al29 (RIC vs MAC) | Busulfan/fludarabine (63%) | Busulfan/cyclophosphamide (59%) | 6 y: 63% vs 59% | 2 y: 26% vs 29% | 2 y: 10% vs 9% |
| Murthy et al75 | Fludarabine/melphalane (66%), busulfan/fludarabine (34%) | Busulfan/fludarabine (65%), busulfan/cyclophosphamide (35%) | 2 y: 57% vs 72%∗ | 1 y: 20% vs 16% | 1 y: 49% vs 41% |
MAC, myeloablative conditioning.
Results are shown for busulfan/fludarabine regimen in both groups.